Astex Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on Astex Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Astex Pharmaceuticals Inc Strategy Report
- Understand Astex Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
View up-to-date information on Astex Pharmaceuticals Inc patents, including inventor and filing insights.
Patent Trends
| Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
|---|---|---|---|---|
| AU2020382379B2 | Grant | Methods of treating lsd1-related diseases and disorders with lsd1 inhibitors | A61K2300/00; A61K31/203; A61K31/40; A61P35/00; A61P35/02; C07B2200/13; C07C63/08; C07D207/14 | March 28, 2024 |
| EP4337638A1 | Application | Feste formen von salzen von 4-[5[(3S)-3-aminopyrrolidin-1-carbonyl -2-[2-FLUOR-4-(2-HYDROXY-2-ETHYLPROPYL)phenyl)phenyl -2-fluor-benzonitril | A61P35/00; C07D207/14 | March 20, 2024 |
| US20230348352A1 | Application | Methods for synthesizing anhydrous lactic acid | C07B2200/13; C07C51/02; C07C51/46; C07C59/08; C07D471/04 | November 02, 2023 |
| TW202329934A | Application | Combinatory therapy for cancer using biphenyl compound and immune checkpoint molecule regulator | A61K2039/505; A61K31/40; A61K39/3955; A61K45/00; A61K45/06; A61P35/00; C07K16/2818 | August 01, 2023 |
| EP4213841A1 | Application | Methods of treating ribonucleotide reductase-related diseases with a ribonucleotide reductase inhibitor | A61K31/4245; A61P35/00; A61P35/02 | July 26, 2023 |
Top Inventors by Filings (Count by publication)
| Name | Count |
|---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer